Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Francesco De Sanctis

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7232-7585; OpenAlex author ID A5082154297. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 12

  1. Transcriptional and Epigenetic Plasticity Drive an Alternative Non-clonal Mechanism of Resistance to Kras G12D Inhibition in Pancreatic Cancer Co-author DOI 10.34133/cancomm.0030↗
  2. Local ablation disrupts immune evasion in pancreatic cancer. Last author DOI 10.1016/j.canlet.2024.217327↗
  3. Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic… Co-author DOI 10.1186/s13046-024-03238-x↗
  4. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.immuni.2024.04.021↗
  5. Axon guidance cue SEMA3A promotes the aggressive phenotype of basal-like PDAC. Co-author DOI 10.1136/gutjnl-2023-329807↗
  6. Cellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC. Last author DOI 10.3389/fimmu.2024.1341079↗
  7. CXCR1/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. Co-author DOI 10.1038/s41416-022-02028-6↗
  8. Talniflumate abrogates mucin immune suppressive barrier improving efficacy of gemcitabine and nab-paclitaxel treatment in pancreatic cancer. Co-author DOI 10.1186/s12967-023-04733-z↗
  9. Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. Co-author DOI 10.1136/jitc-2021-003549↗
  10. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with a… Co-author DOI 10.1136/jitc-2021-002876↗
  11. MAP Kinase inhibition reshapes tumor microenvironment of mouse pancreatic cancer by depleting anti-inflammatory macrophages Co-author DOI 10.1101/759779↗
  12. Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. Co-author DOI 10.1093/carcin/bgy094↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vincenzo Corbo · 11 shared papers, 2019–2026 · strength 1.69
  2. Carmine Carbone · 8 shared papers, 2021–2026 · strength 1.37
  3. Antonio Agostini · 7 shared papers, 2021–2026 · strength 1.21
  4. Geny Piro · 7 shared papers, 2021–2026 · strength 1.16
  5. Giampaolo Tortora · 6 shared papers, 2021–2026 · strength 1.01
  6. Aldo Scarpa · 7 shared papers, 2019–2025 · strength 0.91
  7. Vincenzo Bronte · 6 shared papers, 2019–2026 · strength 0.88
  8. Alessia Caggiano · 4 shared papers, 2023–2026 · strength 0.72
  9. Rita Teresa Lawlor · 5 shared papers, 2019–2024 · strength 0.62
  10. Francesca Lupo · 4 shared papers, 2019–2025 · strength 0.60
  11. Chiara Musiu · 3 shared papers, 2022–2025 · strength 0.48
  12. Salvatore Paiella · 3 shared papers, 2022–2025 · strength 0.48
  13. Gabriella Lionetto · 2 shared papers, 2024–2025 · strength 0.38
  14. Claudio Sette · 2 shared papers, 2021–2026 · strength 0.34
  15. Pietro Delfino · 3 shared papers, 2019–2024 · strength 0.34
  16. Peter J. Bailey · 2 shared papers, 2024 · strength 0.30
  17. Claudio Bassi · 2 shared papers, 2022–2025 · strength 0.27
  18. Roberto Salvia · 2 shared papers, 2022–2025 · strength 0.27
  19. David Arthur Tuveson · 2 shared papers, 2022–2024 · strength 0.26
  20. Gian Luca Rampioni Vinciguerra · 1 shared paper, 2026 · strength 0.23
  21. Sabrina L. D’Agosto · 2 shared papers, 2019–2024 · strength 0.22
  22. Elena Fiorini · 2 shared papers, 2019–2024 · strength 0.22
  23. Lisa Salvatore · 1 shared paper, 2025 · strength 0.21
  24. Matteo Fassan · 2 shared papers, 2019–2022 · strength 0.17
  25. Erica Dugnani · 2 shared papers, 2018–2022 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.